Induced and pre-existing anti-polyethylene glycol antibody in a trial of every 3-week dosing of pegloticase for refractory gout, including in organ transplant recipients

HIGHLIGHTS

• who: Michael S Hershfield and colleagues from the An open label trial was conducted at Duke University Medical Center to evaluate the ability of pegloticase infused every three weeks to maintain pUA below , mg/dL in , patients with refractory, symptomatic gout who were ≥, years old and had serum uric acid concentration >, mg/dLInclusion and exclusion criteria were similar to those in other trials of pegloticase [4, , ], except for the participation of seven organ transplant recipients who were receiving immunosuppressive therapy to prevent graft rejection, and three patients who had received pegloticase in previous phase , or phase , trials . . .
  

   

  

  If you want to have access to all the content you need to log in!

  Thanks :)

  Username or E-mail:

  If you don't have an account, you can create one here.